Can lifecycle management safeguard innovation in the pharmaceutical industry?

Drug Discov Today. 2018 Dec;23(12):1962-1973. doi: 10.1016/j.drudis.2018.10.008. Epub 2018 Oct 17.

Abstract

The pharmaceutical industry invests enormous amounts of resources (>€1 billion and >10years) in the development of new products. External factors such as intensifying foreign competition and greater regulatory demands can negatively affect the profit margin, whereas the R&D productivity diminishes. To stay competitive and to maintain high R&D capabilities for developing new medicinal products, companies must make smart investment decisions to maximize their return on investment. Consequently, the entire lifecycle of a medicinal product must be effectively managed to ensure a sustained development through commercialization. This review critically assesses the current situation and the associated management strategies throughout the lifecycle of a medicinal product.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / standards
  • Drug Evaluation, Preclinical / standards
  • Drug Industry / standards*
  • Drug-Related Side Effects and Adverse Reactions / prevention & control
  • Humans
  • Medicine / standards*
  • Pharmaceutical Preparations / standards*
  • Problem Solving

Substances

  • Pharmaceutical Preparations